Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 12/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28619681 | 1.00 | PTGER4 (0.46) | PTGER4PTGER2ACACBGPR139PHGDH | |
| SCHEMBL29894128 | 0.93 | PTGER4 (0.47) | PTGER4PTGER2ACACB | |
| SCHEMBL18758537 | 0.93 | PTGER4 (0.47) | PTGER4PTGER2ACACB | |
| SCHEMBL28624098 | 0.93 | PTGER4 (0.47) | PTGER4PTGER2ACACB | |
| SCHEMBL18740052 | 0.92 | PTGER4 (0.53) | PTGER4PTGER2ACACB | |
| SCHEMBL18740050 | 0.92 | PTGER4 (0.53) | PTGER4PTGER2ACACB | |
| SCHEMBL18758566 | 0.90 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL28922411 | 0.90 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL18758724 | 0.86 | BRD4 (0.45) | PTGER4ACACBNPSR1 | |
| SCHEMBL28961686 | 0.86 | BRD4 (0.45) | PTGER4ACACBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ACACB 2590/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ACACB 2590/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885ACACB 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.